http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Yong‐,Jin,Yoo, Hyobin,Lee, Chul‐,Ho,Park, Jun Beom,Baek, Hyeonjun,Kim, Miyoung,Yi, Gyu‐,Chul WILEY‐VCH Verlag 2012 Advanced Materials Vol.24 No.41
<P>On page 5565, Gyu‐Chul Yi and co‐workers grow position‐ and morphology‐controlled ZnO nanowalls in prescribed positions on graphene layers. The nanowalls are grown to produce a variety of shapes from simple circles to text at the microscale. The selective growth of high quality ZnO nanowalls is investigated by electron microscopy and optical spectroscopy. The hybrid nanostructure can be exploited to fabricate various nanodevices including microarrays of nanotube LEDs. </P>
( Baek Gyu Jun ),( Young Don Kim ),( Gab Jin Cheon ),( Jeong-ju Yoo ),( Sang Gyune Kim ),( Young Seok Kim ),( Soung Won Jeong ),( Jae Young Jang ),( Ji Hye Lee ),( Hong Soo Kim ),( Sae Hwan Lee ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: It remains uncertain whether antiviral treatment improve surivival in hepatitis B virus (HBV)-hepatocellular carcinoma (HCC) patients receiving palliative therapy. The purpose of this study is to evaluate the role of antiviral therapy in HBV-HCC patients after diagnosis of HCC. Methods: This retrospective study analyzed 113 HBV-HCC patients who underwent transarterial chemoembolization (TACE) in two university hospital. Overall survival (OS) was compared in patients treated with/without antiviral treatment after diagnosis of HCC. Subgroup analysis and Cox regression analysis were performed to determine the efficiency of antiviral treatment and prognostic factors for OS. Results: OS was not different between the patients treated with antiviral treatment (n = 67) and the patients who received no antiviral treatment (n = 46) (P=0.103). Barcelona Clinic Liver Cancer (BCLC) was independent prognostic factors for OS of HBV-related HCC patients who were treated with TACE. By subgroup analysis, antiviral therapy achieved better survival improvement in BCLC stage B and C (P<0.001) but had no survival improvement in BCLC stage 0 and A (P=0.605). Antiviral therapy was one of the independent prognostic factors for patients with BCLC stage B and C (HR 0.230, 95% CI 0.094-0.565, P=0.001). Conclusions: Antiviral therapy did not improve survival of HBV-related HCC patients treated with TACE. However, antiviral therapy shows survival benefit only in BCLC stage B and C disease.
( Baek Gyu Jun ),( Sang Gyune Kim ),( Young Don Kim ),( Gab Jin Cheon ),( Koon Hee Han ),( Jeong-ju Yoo ),( Young Seok Kim ),( Soung Won Jeong ),( Jae Young Jang ),( Sae Hwan Lee ),( Suyeon Park ),( H 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Patients with liver cirrhosis and hepatocellular carcinoma (HCC) are often ineligible for resection or local ablation therapy due to poor liver function and/or difficult location. The aim of this study is to evaluate therapeutic outcomes of stereotactic body radiotherapy (SBRT) combined with transarterial chemoembolization (TACE) compared with TACE alone for HCC measuring less than 5 cm. Methods: From March 2011 to December 2016, 85 patients underwent SBRT with TACE (SBRT-TACE group) and 114 underwent TACE (TACE group) at 4 tertiary hospitals. Local control rate (LCR), progression-free survival (PFS) and overall survival (OS) were compared after propensity-score matching (1:1 ratio). Results: The SBRT-TACE group showed significantly higher 1- and 3-year LCR than the TACE group (91.1% and 89.9%, respectively vs 69.9% and 44.8%, respectively; P<0.001). The SBRT-TACE group showed better 1- and 3-year PFS than the TACE group (56.5% and 32.3%, respectively vs 42.2% and 21.6%, respectively; P=0.022). However, 1-, 3- and 5-year OS was not different between the SBRT-TACE and TACE groups (98.8%, 89.1% and 80.7%, respectively vs 99.7%, 83.3% and 71.0%, respectively; P=0.206). In multivariate analysis, the overall SBRT added to TACE did not contribute to extend PFS. However, in patients with less than 2 tumors, the combined therapy was effective (HR 0.590, 95% CI 0.392-0.889, P=0.012). Conclusions: SBRT-TACE is superior to TACE in terms of LCR. Particularly, SBRT-TACE may be an effective alternative in patients with HCC number (≤2), which is not indicated for resection or local ablation.
( Baek Gyu Jun ),( Young Don Kim ),( Gab Jin Cheon ),( Sang Gyune Kim ),( Young Seok Kim ),( Boo Sung Kim ),( Soung Won Jeong ),( Jae Young Jang ),( Sae Hwan Lee ),( Hong Soo Kim ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: There are no convincing data supporting the routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy( RT) for hepatocellular carcinoma (HCC). The aim of this study was to investigate incidence, clinical significance and risk factors of HBV reactivation during RT. Methods: Medical records of 121 HBsAg (+) HCC patients with radiotherapy were reviewed from March 2007 to February 2016. Patients were divided into 2 groups, 24 patients did not receive antiviral therapy before RT and 97 patients underwent antiviral therapy before RT. We evaluated the factors related to HBV reactivation in HCC patients. Results: During the follow-up, 11 (9.1%) of 121 patients developed HBV reactivation. Compared with non-antiviral group, antiviral group had significantly lower rates of HBV reactivation (5/97, 5.2% vs 6/24, 25%: p = 0.002). The incidence of HBV induced radiation induced liver toxicity (RILT) (2.1% vs 12.5%: p = 0.021) and HBV related hepatitis (3.1% vs 12.5% p= 0.057) were low in antiviral group. In contrast, there were no difference in incidences of overall RILT (p = 0.157) and hepatitis (p= 0.478). In multivariate analysis, absence of antiviral prophylaxis and combined with transarterial chemoembolizatoin (TACE) were the risk factors for reactivation. Conclusions: HBV reactivation can occur after radiotherapy. Combination treatment with TACE and non-antiviral treatment are the major risk factors for HBV reactivation during RT. Preventive therapy should be recommended for the patients supposed to receive RT.
( Baek Gyu Jun ),( Young Don Kim ),( Gab Jin Cheon ),( Sae Hwan Lee ),( Hong Soo Kim ),( Sang Gyune Kim ),( Young Seok Kim ),( Boo Sung Kim ),( Soung Won Jeong ),( Jae Young Jang ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: The aim of this study was to identify parameters that predict radiation induced liver disease (RILD) following stereotactic body radiotherapy (SBRT) in cirrhotic patients with small hepatocellular carcinoma (HCC). Methods: We retrospectively reviewed 84 patients treated with SBRT for small (diameter <3 cm) HCC treated by SBRT between March 2011 and February 2015. RILD was defined as elevated liver transaminases more than five times the upper limit of normal or a worsening of Child-Pugh score by 2 within 3 months after SBRT. All patients were assessed at 1 month and every 3 months after SBRT. Results: Median follow-up was 16.5 (2-56) months after SBRT. Seventeen (18.5%) of the 84 patients developed RILD after SBRT. Multivariate logistic regression analysis showed that Child-Pugh (CP) scores (p < 0.01) was significant parameter to predict RILD in cirrhotic patients. According to linear by linear association model, as CP score increases, the incidence rate of RILD (P<0.01) increases, and the recov- ery rate of RILD (P<0.01) shows a tendency to decrease. The incidence rate of RILD increases at CP score 6 remarkably, and the recovery rate of RILD seems to decrease significantly at CP score 8. In multivariate analysis, CP score 8 was independent prognostic factors of overall survival. (P<0.01) Conclusions: CP score is important factor to predict RILD. The Incidence rate of RILD seems to increase, but does not recover at CP score above 8.
( Baek Gyu Jun ),( Young Don Kim ),( Gab Jin Cheon ),( Eun Seog Kim ),( Eunjin Jwa ),( Sang Gyune Kim ),( Young Seok Kim ),( Boo Sung Kim ),( Soung Won Jeong ),( Jae Young Jang ),( Sae Hwan Lee ),( Ho 대한내과학회 2018 The Korean Journal of Internal Medicine Vol.33 No.6
Background/Aims: The aim of this study was to investigate parameters that predict radiation-induced liver disease (RILD) following stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma (HCC) and to identify the clinical significance of RILD. Methods: We retrospectively reviewed the medical records of 117 HCC patients who were treated by SBRT from March 2011 to February 2015. RILD was defined as elevated liver transaminases more than five times the upper normal limit or a worsening of Child-Pugh (CP) score by 2 within 3 months after SBRT. All patients were assessed at 1 month and every 3 months after SBRT. Results: Median follow-up was 22.5 months (range, 3 to 56) after SBRT. RILD was developed in 29 of the 117 patients (24.7%). On univariate analysis, significant predictive factors of RILD were pretreatment CP score (p < 0.001) and normal liver volume (p = 0.002). Multivariate analysis showed that CP score was a significant predictor of RILD (p < 0.001). The incidence of RILD increased above a CP score of 6 remarkably. The rate of recovery from RILD decreased significantly above a CP score of 8. Survival analysis showed that CP score was an independent prognostic factor of overall survival (p = 0.001). Conclusions: CP score is a significant factor to predict RILD in patients with chronic liver disease. RILD can be tolerated by patients with a CP score ≤ 7. However, careful monitoring of liver function is needed for patients with a CP score 7 after SBRT.
( Baek Gyu Jun ),( Hyuk Jin Moon ),( Sae Hwan Lee ),( Hong Soo Kim ),( Sang Gyune Kim ),( Young Seok Kim ),( Boo Sung Kim ),( Soung Won Jeong ),( Jae Young Jang ),( Young Don Kim ),( Gab Jin Cheon ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: The aim of this study was to compare the renal dysfunction and hypophosphatemia between adefovir dipivoxil(ADF) plus lamivudine( LMV) therapy and ADF monotherapy in chronic hepatitis B(CHB) patients. Methods: Between March 2005 and February 2014, 56 patients treated with 10mg/day ADF plus 100mg LMV(Group A) and 41 patients treated with 10mg/day ADF(Group B) were reviewed in our institution. We evaluated estimated glomerular filtration rate (eGFR), serum creatinine and serum phosphate level at the start of ADV plus LMV and ADF monotherapy and every 3 months. Results: The median treatment duration was 73.6 and 80.1 months in groups A and B, respectively. Increased creatinine level(>0.3mg/dl) was seven patients in group A and one patient in Group B(12.3% vs. 2.4%, p=0.134). Decreased eGFR(>50%) was three patients in group A and no patient in group B(0% vs. 5.3%, p=0.262). Hypophosphatemia occurred 14(26.8%) patients in Group A and 11(26.8%) patients in Group B(p=0.799). Mean serum creatinine levels increased and mean eGFR decreased from baseline to end of treatment in Group A( Creatinine 0.75 ± 0.19 vs 0.87 ± 0.21mg/dl, p<0.01, eGFR 108±16 vs 94±18 ml/min p<0.01 ). Mean serum creatinine creatinine levels and mean eGFR were not changed from baseline to end of treatment in Group B( Creatinine 0.79 ± 0.16 vs 0.81 ± 0.16mg/dl, p=0.338, eGFR 102±17 vs 100±18 ml/min p=0.410). Conclusions: Both long-term ADF plus LMV therapy and ADF monotherapy dose not deteriorate significant renal function. However, mild decrease in eGFR and increase of serum creatinine occurred in ADF plus LMV therapy compared to ADF monotherapy.
( Baek Gyu Jun ),( Sang Gyune Kim ),( Young Don Kim ),( Gab Jin Cheon ),( Jeong-ju Yoo ),( Young Seok Kim ),( Soung Won Jeong ),( Jae Young Jang ),( Sae Hwan Lee ),( Hong Soo Kim ),( Sang-wook Yi ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Body mass index (BMI) is known to be associated with higher risk of hepatocellular carcinoma (HCC) in the general population. However, the association between BMI and risk of HCC in patients with various liver disease is not well understood. Methods: We used data from National Health Insurance Service (NHIS) that provides compulsory health insurance coverage and national health screening for all citizens in the Republic of Korea. Hazard ratios (HRs) were calculated using Cox regression models to examine associations between body mass index (BMI) and risk of HCC. We included 15016551 adults (aged 18-99 years) who underwent health examinations between 2003 and 2006, in the NHIS database. Participants were classified into six groups according to the liver diseases; liver cirrhosis (LC), hepatitis B or C virus infection (HBVHCV), other liver disease (O-LD), unidentified liver disease with alanine aminotransferase (ALT) ≥40 or aspartate aminotransferase (AST) ≥40 (ALT40), no known liver diseases with 20≤ALT<40 or 20≤AST<40 IU/ml (ALT2040), and ALT<20 and AST<20 (ALT20). Results: During mean 13.7 years of follow-up. HCC occurred in 71570 individuals. In total population, BMI had a non-linear association with HCC. In BMI above 25 kg/m², BMI was positively associated with risk of HCC regardless of liver disorder. In the multivariable adjusted analysis, the HR per 5 kg/m² increase in BMI above 25 kg/m² was 1.48 (95% CI 1.44-1.52) in total population, 1.11 (95% CI 1.00-1.23) in LC, 1.12 (95% CI 1.44-1.52) in HBVHCV, 1.32 (95% CI 1.22-1.44) in O-LD, 1.07 (95% CI 1.03-1.12) in ALT40, 1.47 (95% CI 1.38-1.57) in ALT2040, 1.67 (95% CI 1.32-2.09) in ALT20. In the subgroup analysis for the HCC high-risk group, the HR of HCC (95% CI) for a 5 kg/m2 increase in BMI was 1.21 in HBV-LC (1.01-1.46), 1.13 in other LC (1.08-1.19) and 1.15 in HBV without LC (1.04- 1.27), 1.14 in HCV without LC (0.92 -1.40) and 1.05 in HCV-LC (0.64-1.74). Associations between BMI and risk of HCC in HBV (HR; 1.46 vs 1.05), HCV (HR; 1.30 vs 0.92) and LC (HR; 1.28 vs 1.02) patients were stronger in female than in male. Conclusions: Our study showed that BMI was positively associated with risk of HCC regardless of liver disorder in BMI above 25 kg/m². As the severity of liver disease weakened, the association between increased BMI and HCC became stronger. Inpatients with HBV, HCV, and LC, the harmful effects of higher BMI on HCC risk was stronger in women than in men.